Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Evoke Pharma, Inc. (NASDAQ:EVOK)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.78 and traded as low as $3.44. Evoke Pharma shares last traded at $3.62, with a volume of 73,780 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Evoke Pharma in a report on Tuesday. They issued a “sell” rating on the stock.

Evoke Pharma Stock Down 22.3 %

The stock has a market cap of $5.38 million, a PE ratio of -0.33 and a beta of 0.16. The business’s fifty day moving average is $4.68 and its 200 day moving average is $4.78.

Institutional Trading of Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC increased its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities and Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.